Effect of intralesional vitamin D in treatment of keloid

Phase 3

Recruiting

• Conditions: Keloid.; Hypertrophic scar; L91.0

• Registration Number: IRCT20220902055857N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Willingness and cooperation to participate in the study
All patients with two or more keloids
The duration of lesions should be less than 5 years and they have not been treated yet
keloids with different sizes up to 5 cm and in different parts of the body

Exclusion Criteria

keloid on face
active infection in or near the keloid site
pregnant or lactating patients
patients with underlying diseases such as diabetes, mental illness, cancer and heart disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Keloid score in the Vancouver Scar scale. Timepoint: Vancouver scar scale upon arrival, 3, 6, 9, 12, 15 weeks after each injection session until the lesion is completely flattened or up to 6 sessions. Method of measurement: Vancouver scar scale.

Secondary Outcome Measures

Name	Time	Method
Patient satisfaction from treatment. Timepoint: End of treatment. Method of measurement: Visual Analogue Scale.